alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
exh10_19.htm


    EXHIBIT
10.19

    Compensation
Arrangements for Thomas G. Yetter

    January
1, 2007

    


    


    The
following is a summary of the compensation arrangement effective January 1, 2007
for Thomas G. Yetter in his capacity as Senior Vice President and Chief
Financial Officer and Director of the Company.  On January 29, 2009, Mr.
Yetter provided the Company with letters of resignation from the Board of
Directors of the Company and from all Officer and Director positions of the
Company and its subsidiaries, effective January 19, 2009.

    


    Annual Base Salary. 
$222,600

    


    Annual and Long-Term Incentive
Compensation Plans. Participation in the Company’s Incentive Bonus Plan,
the 2005 Stock Incentive Plan and the 2005 Executive Bonus and Restricted Stock
Plan.

    


    Benefit Plans and Other
Arrangements. Mr. Yetter was eligible to participate in the
Company’s broad-based programs including health, disability and life insurance
programs, the Frozen Food Express Industries, Inc. 401 (k) Savings Plan, and the
FFE Transportation Services, Inc. 401(k) Wrap Plan.  He was also
eligible to participate in the Key Employee Supplemental Medical
Plan.

    


    Change in Control Agreements.
Mr. Yetter and the Company entered into a Change in Control Agreement which
entitles executive officers severance benefits in the event of a “change in
control” of the Company during the term of his employment.

    


    Perquisites.
Mr. Yetter was eligible to participate in certain programs offered by
the Company, including automobile mileage reimbursement for business purposes
plus a $500 per month automobile allowance and a Christmas bonus equal to one
week’s annual base salary.
**EXHIBIT32.2**

 

**Alpha ProTech, Ltd.**

 

Alpha Pro Tech, Ltd.

 

CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2003

 

In connection with theQuarterly Report of Alpha Pro Tech, Ltd. (the “Company) on Form 10-Q for theperiod ending September 30, 2004 as filed with the Securities and ExchangeCommission on the date hereof (the “Report”), I, Lloyd Hoffman, Chief FinancialOfficer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adoptedpursuant to section 906 of the Sarbanes-Oxley Act of 2003, that:

 

(1)                                  TheReport fully complies with the requirements of section 13(a) or 15(d) of theSecurities Exchange Act of 1934 (15 U.S.C.78m or 78o (d));and

 

(2)                                  Theinformation contained in the Report fairly presents, in all material respects,the financial condition and result of operations of the Company.

 

 
| DATE:  | November 1, 2004 |   | BY:                      | /s/Lloyd  Hoffman |
|--------|------------------|--------|--------------------------|-------------------|
|   |             |   | LLOYD  HOFFMAN           |
|   |             |   | CHIEF  FINANCIAL OFFICER |

 

1

----
1 In The



### Court of Appeals

Ninth District of Texas at Beaumont

_________________

NO. 09

- 13

- 00 25 6

- CV



### _________________

SAEED ALLY

, Appellant

V.

MEDICAL CENTER OF SOUTHEAST TEXAS LP , Appellee

________________________________________________________________________

On Appeal from the 136th District Court

Jefferson County, Texas

Trial Cause No. A

- 189,012

________________________________________________________________________

MEMORANDUM OPINION

Saeed Ally filed a notice of appeal but failed to file a brief. On November 7,

2013 , we notified the parties that the brief had not been filed and warned the

appellant that his failure to file a brief could result in a dismissal of the appeal for

want of p rosecution. On December 13 , 2013, we notified the parties that the appeal

would be submitted to the Court without oral argument. See Tex. R. App. P. 39.8.

In the absence of a brief assigning error for appellate review, we dismiss the appeal2 for want of pro secution. See Tex. R. App. P. 38.8(a)(1); see also Tex. R. App. P.

42.3(b).

APPEAL DISMISSED.

________________________________ STEVE McKEITHEN

Chief Justice

Submitted on January 3, 2014

Opinion Delivered January 16, 2014

Before McKeithen, C.J., Horton and Johnson , JJ.
EXHIBIT 10.32


 





	 	 	 



 


 


March 5, 2013


 


 


 


Mr. Jerry Swinford 


Coil Tubing Technology,
Inc. 


19511 Wied Rd,
Suite E 


Spring, Texas
77388


 


 


 


 


 Dear Mr. Swinford:


  


	 	At your request, we are submitting the following proposal to provide professional accounting and consulting services, to Coil Tubing Technology, Inc.:


 


	 	1.  Our fee will be $5,000.00 per month for professional time, which is detailed in the following.


 


	 	2.   In addition, we will bill you for out-of-pocket expenses (For example, travel expenses).  These expenses will be discussed with you before such charges are incurred, if any.  Out-of-pocket expenses will not include travel within the Harris County limits.


 


	 	3.   In short, our firm will act as your chief financial officer which will allow you to pay attention to aspects of your business other than financial affairs.  Professional services which we will provide include the following:


 


	 	a)   Assistance during each quarter and annually for filings with the Security and Exchange Commission





 


	 	
        b)  Coordination with company personnel in preparing and monitoring such filings

         

        

        c)   We will sign, as chief financial officer, all filings with the Securities and Exchange
        Commission. 



 






    	1



    	 



    

 


 


Mr. Jerry Swinford


 


Coil Tubing Technology,
Inc.


Page2


 


 


 


	 	d)   It is anticipated that we will spend on the average forty (40) hours per month in providing our accounting services.


 





	 	4.   Additional services will be determined under a separate engagement letter and billed at our standard hourly rate of $300.00/hr.
	 	 
	 	5.   Payment for our services will be due as follows: $5,000.00 on the 1st day of each month.


 


    


 


The above structure
commences March 1, 2013.


 


We look forward
to your response to our proposal.  If you are in agreement with the above please sign in the space provided below.
Nos. 997 and 998.

#### Edward Katzinger Co. *v.*Chicago Metallic Mfg. Co.

April 29, 1946.

*Charles J. Merriam*for petitioner.

*Max W. Zabel*and *Ephraim Banning*for respondent.

Petition for writs of certiorari to the Circuit Court of Appeals for the Seventh Circuit granted.
CLD

- 283 NOT PRECEDENTIAL
UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT

___________ No. 17

- 2195

___________ IN RE: MICHAEL BULLOCK , Petitioner

____________________________________ On a Petition for Writ of Mandamus fr om the United States District Court for the Eastern District of Pennsylvania

(Related to E. D. Pa . Civ. No. 2

- 1 6

- cv - 0 1456 )

____________________________________ Submitted Pursuant to Rule 21, Fed. R. App. P.

June 15, 2017
Before: SHWARTZ, NYGAARD and FISHER , Circuit Judges

(Opinion filed : June 22, 2017 )

_________ OPINION *

_________ PER CURIAM
Petitioner Michael Bullock seeks a writ of mandamus pursuant to 28 U.S.C. §
1651 , to compel the United States District Court for the Eastern District of Pennsylvania
to issu e a ruling on his habeas petition filed pursuant to 28 U.S.C. § 22 5 4

.

* T his disposition is not an opinion of the full Court and pursuant to I.O.P. 5.7 does not constitute binding precedent.2

Bullock filed his § 2254 petition in March 201 6

. The Government filed a response to the habeas petition in June 201 6. Two months later, the Magistrate Judge to whom the petition had b een referred is sued a Report recommending that the petition be denied

. Bullock filed objections to that Report and Recommendation in early September 2016

. At the time Bullock submitted his mandamus petition to this Court, his habeas petition
had been rip e and pending for a bout nine months . However, the record reflects that the
District Court d ismissed the habeas petition by an O rder entered on June 5, 2017 , prior to the Clerk’s receipt of Bullock ’s motion for leave to proceed with this mandamus petition
in forma pauperis

. As the District Court has ruled on the habeas petition, Bullock has received the relief sought in his mandamus petition. Thus, we will dismiss the petition as

moot. See Blanciak v. Allegheny Ludlum Corp. , 77 F.3d 690, 698

- 99 (3d Cir. 1996)

. If Bullock wishes to seek appellate review of the District Court’s adverse decision with respect to his habeas petition, he should file his notice of appeal in the District Court within the time period set forth in F ed. R. App. P. 4(a)(1)(A )

.
I 

108TH CONGRESS 

1ST SESSION H. R. 938

To prohibit Federal payments to any individual, business, institution, or 

organization that engages in human cloning. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 26, 2003

Mr. PAUL introduced the following bill; which was referred to the Committee 

on Energy and Commerce 

A BILL

To prohibit Federal payments to any individual, business, 

institution, or organization that engages in human cloning.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Human Cloning Pre5 vention Act of 2003’’. 

6 SEC. 2. PROHIBITION. 

7 (a) GENERAL RULE.—Except as provided in sub8 section (b), no Federal agency shall—

9 (1) make any grant, contract, or other pay10 ment; or 
2

•HR 938 IH 

1 (2) enter into any obligation for making any 

2 such grant, contract, or payment, 

3 to any individual, business, institution, or organization 

4 that within the past 1 year has engaged in human cloning, 

5 or to any individual, business, institution, or organization 

6 that controls, is controlled by, or is under common control 

7 with any individual, business, institution, or organization 

8 that within the past 1 year has engaged in human cloning. 

9 (b) EXCEPTION.—Subsection (a)(1) shall not apply 

10 to any payment a Federal agency is obligated to make. 

11 SEC. 3. DEFINITION. 

12 For purposes of this Act, the term ‘‘human cloning’’ 

13 means human asexual reproduction, accomplished by in14 troducing nuclear material from one or more human so15 matic cells into a fertilized or unfertilized oocyte whose 

16 nuclear material has been removed or inactivated so as 

17 to produce a living organism (at any stage of development) 

18 that is genetically identical to an existing or previously ex19 isting human organism.

Æ
Exhibit 31.2

CERTIFICATION



I, John E. Baker, certify that:



1.

I have reviewed this quarterly report on Form 10-Q of Stratus Properties Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of  the end of the period covered by this report based on such evaluation; and

(c)

Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and

5.

The registrants other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting.

Date:  November 14, 2003





/s/ John E. Baker

John E. Baker

Senior Vice President

and Chief Financial Officer
#### The People of the State of New York, Respondent, v Ronald Hardy, Appellant.

[852 NYS2d 848]

Since the defendant had already been released on parole in connection with his 1996 conviction when he moved for *780resentencing pursuant to the Drug Law Reform Act of 2005 (L 2005, ch 643), he was no longer eligible for resentencing, and the court could therefore properly deny the motion without first holding a hearing *(see People v McCurdy,*46 AD3d 843 [2007], *lv dismissed*9 NY3d 1036 [2008]; *People v Corley,*45 AD3d 857 [2007]). Rivera, J.P., Lifson, Miller, Carni and Eng, JJ., concur.
EXHIBIT 10.18


 


AMENDMENT NUMBER 2 TO THE INVESTMENT
AGREEMENT


 


This Amendment Number 2 to the Investment
Agreement by and between the Company and the Investor, dated June 14, 2010 and as amended on May 31, 2012 (the “Investment
Agreement”) is dated as of February 7, 2013, between BNC Bancorp, a corporation organized under the laws of North Carolina
(the “Company”), and Aquiline BNC Holdings LLC, a Delaware limited liability company (including its successors
and assigns, the “Investor”).


 


RECITALS


 


WHEREAS, the Investor intends to convert
its 1,804,566 shares of Series B Preferred Stock into 1,804,566 shares of Non-Voting Common Stock, pursuant to the terms of the
Series B Preferred Stock (as amended on February 7, 2013), and is, concurrently with the execution of this amendment, providing
written notice to the Company requesting that the Company convert such shares of Series B Preferred Stock into Non-Voting Common
Stock (the “Conversion”); and


 


WHEREAS, in connection with the Conversion,
the Company and the Investor intend to amend the Investment Agreement.


 


NOW, THEREFORE, the Company and the Investor
hereby agree that Section 4.7 of the Investment Agreement is hereby amended and restated as follows:


 


Extension Period. Notwithstanding
anything to the contrary contained in this Agreement, if, during the 180-day period commencing on February 7, 2013, there exists
a period (the “Section 16(b) Period”) during which the exercise by the Investor of its rights pursuant to Section
4.2 (or the purchase of New Securities in connection with such exercise) would result in liability under Section 16(b) of the
Exchange Act, as amended, or the rules and regulations promulgated thereunder, the period during which such rights pursuant to
Section 4.2 may be exercised shall be extended for the equivalent number of days of such Section 16(b) Period.


 


*       *       *


 


IN WITNESS WHEREOF, the parties hereto have caused this Amendment
Number 2 to the Investment Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.


 


	 	BNC BANCORP
	 	 
	 	By: /s/ David B. Spencer
	 	Name: David B. Spencer
	 	Title: EVP/CFO
	 	 
	 	AQUILINE BNC HOLDINGS LLC
	 	a Delaware limited liability company
	 	 
	 	
        By: Aquiline Financial Services Fund L.P., member of 

	 	Aquiline BNC Holdings LLC
	 	 
	 	By: Aquiline Capital Partners GP LLC, general partner
	of Aquiline Financial Services Fund L.P.
	 	 
	 	By: /s/ Sandra Wijnberg
	 	Name:   Sandra Wijnberg
	 	Title:    Authorized Person
EX-10.9(b)



 Exhibit 10.9(b) 

AMENDMENT NO. 1 
 TO ARATANA THERAPEUTICS, INC. 
 2010 EQUITY INCENTIVE PLAN

 Approved by the Board of Directors: October 28, 2011 

Approved by the Stockholders: October 28, 2011 

THIS AMENDMENT NO. 1 TO 2010 ARATANA
THERAPEUTICS, INC. EQUITY INCENTIVE PLAN (this “Amendment”) is made and entered into as of November 1, 2011. 

WHEREAS, the Board of Directors (the “Board”) and the requisite Stockholders
(the “Stockholders”) of Aratana Therapeutics, Inc., a Delaware corporation (the “Company”), approved and adopted the 2010 Aratana Therapeutics, Inc Equity Incentive Plan (the
“Plan”) on December 23, 2010; 
 WHEREAS, capitalized terms
used and not otherwise defined herein shall have the meanings given to them in the Plan; and 

WHEREAS, in accordance with Section 11.2 of the Plan, the Board and the Stockholders desire to
amend the Plan as set forth in this Amendment. 
 NOW, THEREFORE, BE
IT RESOLVED, that the Plan is hereby amended as follows: 
  

	 	1.	AMENDMENT TO SECTION 4.1. Section 4.1 of the Plan is hereby amended by replacing 1,500,000 shares
with 2,500,000 shares. 

  

	 	2.	MISCELLANEOUS. 

  

	 	a.	No Other Amendment. Except as specifically amended by this Amendment, the terms and conditions of the Plan shall remain unchanged and in full force and effect.


  

	 	b.	Execution by Facsimile. The exchange of copies of this Amendment and of signature pages thereto by facsimile transmission or by e-mail transmission in portable
digital format, or similar format, shall constitute effective execution and delivery of such instrument(s) and may be used in lieu of the original Amendment for all purposes. 


[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 







 IN WITNESS WHEREOF, the Company has
caused this Amendment to the Plan to be executed as of the date first above written. 
  

			
	ARTANA THERAPEUTICS, INC.
		
		 	 /s/ Linda Rhodes

	By:	 	Linda Rhodes
	Its:	 	Chief Executive Officer


 [SIGNATURE PAGE TO AMENDMENT NO. 1 TO 2010 EQUITY INCENTIVE PLAN]
```

[Congressional Bills 108th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 188 Engrossed in House (EH)]

                 In the House of Representatives, U.S.,

                                                        April 10, 2003.
    Resolved, That upon adoption of this resolution it shall be in order to 
consider the conference report to accompany the bill (S. 151) to amend title 18, 
United States Code, with respect to the sexual exploitation of children. All 
points of order against the conference report and against its consideration are 
waived. The conference report shall be considered as read.
            Attest:

                                                                          Clerk.
```
Exhibit 10.14

Compensation of Named Executive Officers of Curis, Inc.

As of March 30, 2006, following are
the base salaries, on an annual basis, of the named executive officers (as defined in Item 402(a)(3) of Regulation S-K) of Curis, Inc.:



|                                                               |  |   |        
|-------------------------------------------------------------- |  | - | -------
|Daniel R. Passeri                                              |  | $ | 375,000
|President and Chief Executive Officer                          |  |   |        
|                                                               | 
|Lee L. Rubin                                                   |  | $ | 325,000
|Senior Vice President of Research and Chief Scientific Officer |  |   |        
|                                                               | 
|Michael P. Gray                                                |  | $ | 235,000
|Vice President of Finance and Chief Financial Officer          |  |   |        
|                                                               | 
|Mark W. Noel                                                   |  | $ | 195,000
|Vice President, Technology Management and Business Development |  |   |        
|                                                               | 
|Mary Elizabeth Potthoff                                        |  | $ | 190,000
|Vice President, General Counsel                                |  |   |        

In addition, each of the named executive officers listed above is eligible to receive stock
options and stock awards under the 2000 Stock Incentive Plan of Curis, Inc.
<TABLE> <S> <C>

<ARTICLE> 5
<CIK> 0001003513
<NAME> STAC, INC.
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          SEP-30-1997
<PERIOD-START>                             OCT-01-1996
<PERIOD-END>                               DEC-31-1996
<EXCHANGE-RATE>                                      1
<CASH>                                          30,519
<SECURITIES>                                    37,284
<RECEIVABLES>                                    6,402
<ALLOWANCES>                                       351
<INVENTORY>                                        415
<CURRENT-ASSETS>                                75,584
<PP&E>                                           9,178
<DEPRECIATION>                                   5,234
<TOTAL-ASSETS>                                  86,327
<CURRENT-LIABILITIES>                            4,742
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        73,585
<OTHER-SE>                                       7,736
<TOTAL-LIABILITY-AND-EQUITY>                    86,327
<SALES>                                         10,896
<TOTAL-REVENUES>                                10,896
<CGS>                                            1,053
<TOTAL-COSTS>                                    1,053
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                  3,338
<INCOME-TAX>                                     1,134
<INCOME-CONTINUING>                              2,204
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     2,204
<EPS-PRIMARY>                                      .07
<EPS-DILUTED>                                      .07
        

</TABLE>
STATE OF LOUISIANA

COURT OF APPEAL, FIRST CIRCUIT

JESSICA MILLS AND DONNA NO. 2022 CW 1019

RUSSELL

VERSUS

USAA D/ B/ A GARRISON PROPERTY

AND CASUALTY INSURANCE CO., 

EZMEE HUTTON, AND LIBERTY SEFTMABER 19, 2022

PERSONAL INSURANCE CO. 

In Re: Garrison Property and Casualty Insurance Company and

Ezmee Hutton, applying for supervisory writs, 19th

Judicial District Court, Parish of East Baton Rouge, 

No. 692, 222. 

BEFORE: THERIOT, CHUTZ, AND HESTER, JJ. 

WRIT DENIED. The criteria set forth in Herlitz

Construction Co., Inc. v. Hotel Investors of New Iberia, Inc., 

396 So. 2d 878 ( La. 1981) ( per curiam) are not met. 

MRT

WRC

Hester, J., dissents. 

COURT OF APPEAL, FIRST CIRCUIT

DEPUTY CLERK OF COURT

FOR THE COURT